These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11168988)

  • 1. Endogenous guanidino compounds as uremic neurotoxins.
    De Deyn PP; D'Hooge R; Van Bogaert PP; Marescau B
    Kidney Int Suppl; 2001 Feb; 78():S77-83. PubMed ID: 11168988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guanidino compounds as uremic (neuro)toxins.
    De Deyn PP; Vanholder R; Eloot S; Glorieux G
    Semin Dial; 2009; 22(4):340-5. PubMed ID: 19708978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convulsive action and toxicity of uremic guanidino compounds: behavioral assessment and relation to brain concentration in adult mice.
    D'Hooge R; Pei YQ; Marescau B; De Deyn PP
    J Neurol Sci; 1992 Oct; 112(1-2):96-105. PubMed ID: 1469446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture.
    De Deyn PP; Macdonald RL
    Ann Neurol; 1990 Nov; 28(5):627-33. PubMed ID: 2135950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guanidino compound levels in brain regions of non-dialyzed uremic patients.
    De Deyn PP; Marescau B; D'Hooge R; Possemiers I; Nagler J; Mahler C
    Neurochem Int; 1995 Sep; 27(3):227-37. PubMed ID: 8520461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ontogenetic differences in convulsive action and cerebral uptake of uremic guanidino compounds in juvenile mice.
    D'Hooge R; Pei YQ; Marescau B; De Deyn PP
    Neurochem Int; 1994 Mar; 24(3):215-20. PubMed ID: 8025530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of NaCN on currents evoked by uremic retention solutes in dissociated mouse neurons.
    Torremans A; D'Hooge R; Van de Vijver G; Marescau B; Vanholder R; Lameire N; De Deyn PP; Van Bogaert PP
    Brain Res; 2004 May; 1008(1):107-12. PubMed ID: 15081387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins.
    D'Hooge R; Van de Vijver G; Van Bogaert PP; Marescau B; Vanholder R; De Deyn PP
    Kidney Int; 2003 May; 63(5):1764-75. PubMed ID: 12675852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uraemic guanidino compounds inhibit gamma-aminobutyric acid-evoked whole cell currents in mouse spinal cord neurones.
    D'Hooge R; De Deyn PP; Van de Vijver G; Antoons G; Raes A; Van Bogaert PP
    Neurosci Lett; 1999 Apr; 265(2):83-6. PubMed ID: 10327174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum guanidino compound levels in uremic pediatric patients treated with hemodialysis or continuous cycle peritoneal dialysis. Correlations between nerve conduction velocities and altered guanidino compound concentrations.
    De Deyn PP; Robitaille P; Vanasse M; Qureshi IA; Marescau B
    Nephron; 1995; 69(4):411-7. PubMed ID: 7777105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The uremic guanidino compound guanidinosuccinic acid induces behavioral convulsions and concomitant epileptiform electrocorticographic discharges in mice.
    D'Hooge R; Pei YQ; Manil J; De Deyn PP
    Brain Res; 1992 Dec; 598(1-2):316-20. PubMed ID: 1486493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum guanidino compound levels and clearances in uremic patients treated with continuous ambulatory peritoneal dialysis.
    De Deyn PP; Marescau B; Swartz RD; Hogaerth R; Possemiers I; Lowenthal A
    Nephron; 1990; 54(4):307-12. PubMed ID: 2325795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum guanidino compound levels and the influence of a single hemodialysis in uremic patients undergoing maintenance hemodialysis.
    De Deyn P; Marescau B; Lornoy W; Becaus I; Van Leuven I; Van Gorp L; Lowenthal A
    Nephron; 1987; 45(4):291-5. PubMed ID: 3587469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting serum and urinary guanidinosuccinic acid levels in normal and uremic subjects.
    Kopple JD; Gordon SI; Wang M; Swendseid ME
    J Lab Clin Med; 1977 Aug; 90(2):303-11. PubMed ID: 886215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epilepsy and the GABA-hypothesis a brief review and some examples.
    De Deyn PP; Marescau B; MacDonald RL
    Acta Neurol Belg; 1990; 90(2):65-81. PubMed ID: 2164316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic renal failure and guanidino compounds].
    Kinoshita T
    Yakugaku Zasshi; 1997 Nov; 117(10-11):673-80. PubMed ID: 9414581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide in uremia: effects of several potentially toxic guanidino compounds.
    De Deyn PP; Vanholder R; D'Hooge R
    Kidney Int Suppl; 2003 May; (84):S25-8. PubMed ID: 12694302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal handling of guanidino compounds in rat and rabbit.
    Levillain O; Marescau B; De Deyn PP
    J Physiol; 1997 Mar; 499 ( Pt 2)(Pt 2):561-70. PubMed ID: 9080382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral toxicity of guanidinosuccinic acid in adult and young mice.
    D'Hooge R; Pei YQ; Marescau B; De Deyn PP
    Toxicol Lett; 1992 Dec; 64-65 Spec No():773-7. PubMed ID: 1471235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guanidino compounds in the sera of uremic patients and in the sera and brain of experimental uremic rabbits.
    Matsumoto M; Kishikawa H; Mori A
    Biochem Med; 1976 Aug; 16(1):1-8. PubMed ID: 1008865
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.